Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 7/20 | 0.56 |
| ▸ | MMP2 | P08253 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20494524 | 0.89 | ALOX15 (0.64) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL30071378 | 0.89 | ALOX15 (0.64) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL19921276 | 0.89 | ALOX15 (0.56) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL31058816 | 0.88 | KDM4E (0.74) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL830789 | 0.88 | KDM4E (0.74) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL5623372 | 0.85 | KDM4E (0.78) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL17368519 | 0.84 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4907791 | 0.84 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL71101 | 0.84 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL30220514 | 0.83 | FLT3 (0.60) | ALOX15KDM4EALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| CN-118530160-A | Aromatic heterocyclic compound, preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| EP-3339305-B1 | INDOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF IN PHARMACEUTICAL DRUG | ZHEJIANG HISUN PHARM CO LTD (CN) | 2022-05-04 | — | — | EP | disclosed |
| CN-109748840-B | Synthetic method of 2-substituted indole derivative | 中国医学科学院药物研究所 | 2021-12-07 | — | — | CN | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | SANOFI (FR) | 2005-06-09 | — | — | US | disclosed |
| US-20050096321-A1 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | SANOFI (FR) | 2005-05-05 | — | — | US | disclosed |
| EP-1003504-B1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| US-6573377-B1 | Antitumor agent capable of showing its efficacy even against 5- FU drug resistant tumors | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| CN-1320122-A | Pyrazole derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 2001-10-31 | — | — | CN | disclosed |
| EP-1103551-A1 | PYRAZOLE DERIVATIVES AND SALTS THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | HRH4, IDO1, HTR4 | ALOX15 808/4885KDM4E 3162/4885ALDH1A1 1008/4885 |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | ALOX15 3474/4885KDM4E 2577/4885ALDH1A1 2510/4885 |
| US-20050096321-A1 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | HTR3C, CYP3A43, IDO1 | ALOX15 404/4885KDM4E 2487/4885ALDH1A1 616/4885 |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | ALOX15 1739/4885KDM4E 4088/4885ALDH1A1 2700/4885 |
| US-11639354-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | ALOX15 3474/4885KDM4E 2577/4885ALDH1A1 2510/4885 |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | ALOX15 1914/4885KDM4E 3717/4885ALDH1A1 1888/4885 |
| US-12202829-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | ALOX15 3474/4885KDM4E 2577/4885ALDH1A1 2510/4885 |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | ALOX15 3474/4885KDM4E 2577/4885ALDH1A1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.